Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist approved in the United States under different brand names for type 2 diabetes and for chronic weight management, with further indications added since - including cardiovascular risk reduction and, under accelerated approval, a liver indication. It has one of the largest randomised trial records in modern medicine and well-documented gastrointestinal side effects.

An evidence-first summary of semaglutide: what it is, the human trial record, its FDA approval status, documented risks and remaining unknowns.

A GLP-1 receptor agonist with one of the largest clinical trial records in modern medicine.

Key takeaways

How it works

GLP-1 is released by the gut after eating. Semaglutide mimics it with a much longer duration of action, so the satiety and insulin-regulating signals persist rather than fading within minutes. Slower gastric emptying contributes to feeling full, and central appetite signalling reduces how much food feels necessary.

What the trials measured

The clinical programme includes randomised placebo-controlled trials with pre-specified endpoints in glucose control, body weight and cardiovascular events. That design is why regulators can describe both benefit and harm with reasonable precision - and why this page can say more than most pages in this section.

Where the caution belongs

Approval applies to specific indications and populations. Use outside those, use without monitoring, and use of compounded or online products are all different situations with different risk profiles. Regulators have issued warnings about compounded and counterfeit semaglutide products.

Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.

Frequently asked questions

Is semaglutide a steroid?

No. It is a peptide analogue of the naturally occurring gut hormone GLP-1.

Does weight come back after stopping?

Trials with a withdrawal phase generally observed substantial regain after discontinuation, which is why it is framed as a long-term treatment for a chronic condition.

Are compounded versions equivalent?

No. Compounded preparations are not FDA-approved products. The FDA has repeatedly warned about dosing errors, counterfeits and misleading marketing in this supply route, and in 2026 issued warning letters to telehealth companies promoting compounded GLP-1 products as equivalent to approved medicines. The FDA's GLP-1 safety page is linked in the sources.

Is there an oral form?

Yes. Oral semaglutide tablets are approved in the United States, and an oral product does not necessarily carry the same indications as the injectable products. The current prescribing information for each brand is linked in the regulatory sources above.

Related on Beiing

Sources

  1. FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
  2. Drugs@FDA - approved drug products and labels - U.S. Food and Drug Administration
  3. DailyMed - FDA prescribing information search - U.S. National Library of Medicine
  4. FDA - FDA's concerns with unapproved GLP-1 drugs used for weight loss - U.S. Food and Drug Administration
  5. ClinicalTrials.gov - U.S. National Library of Medicine
  6. PubMed - National Library of Medicine - NIH

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.